Literature DB >> 24890587

Posaconazole concentrations in human tissues after allogeneic stem cell transplantation.

Ola Blennow1, Erik Eliasson2, Tommy Pettersson2, Anton Pohanka2, Attila Szakos3, Ibrahim El-Serafi4, Moustapha Hassan4, Olle Ringdén5, Jonas Mattsson5.   

Abstract

Few data have been published regarding posaconazole tissue concentrations in humans. We analyzed tissue concentrations in biopsy specimens taken at autopsy from seven patients who received posaconazole prophylaxis because of graft-versus-host disease. The results were compared to plasma concentrations collected before death. Tissue concentrations suggestive of an accumulation of posaconazole were found in the heart, lung, liver, and kidney but not in the brain.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24890587      PMCID： PMC4136075          DOI： 10.1128/AAC.03252-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Intracellular concentrations of posaconazole in different compartments of peripheral blood.

Authors:  Fedja Farowski; Oliver A Cornely; Jörg J Vehreschild; Pia Hartmann; Tim Bauer; Angela Steinbach; Maria J G T Rüping; Carsten Müller
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma.

Authors:  S H Jang; P M Colangelo; J V S Gobburu
Journal:  Clin Pharmacol Ther       Date:  2010-05-26       Impact factor: 6.875

3.  In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Authors:  F Sabatelli; R Patel; P A Mann; C A Mendrick; C C Norris; R Hare; D Loebenberg; T A Black; P M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

Authors:  Oliver A Cornely; Johan Maertens; Drew J Winston; John Perfect; Andrew J Ullmann; Thomas J Walsh; David Helfgott; Jerzy Holowiecki; Dick Stockelberg; Yeow-Tee Goh; Mario Petrini; Cathy Hardalo; Ramachandran Suresh; David Angulo-Gonzalez
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

5.  Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis.

Authors:  Paolo Campoli; David S Perlin; Arnold S Kristof; Theodore C White; Scott G Filler; Donald C Sheppard
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

6.  Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration.

Authors:  Anders Lignell; Elisabeth Löwdin; Otto Cars; Erja Chryssanthou; Jan Sjölin
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

7.  Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole.

Authors:  Saskia Kuipers; Roger J M Brüggemann; Ruud G L de Sévaux; John P F A Heesakkers; Willem J G Melchers; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

8.  Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.

Authors:  John E Conte; Catherine DeVoe; Emily Little; Jeffrey A Golden
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

9.  Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.

Authors:  Gopal Krishna; Allen Moton; Lei Ma; Matthew M Medlock; James McLeod
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

10.  Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.

Authors:  John E Conte; Jeffrey A Golden; Gopal Krishna; Marina McIver; Emily Little; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191
View more
  8 in total

1.  Low Central Nervous System Posaconazole Concentrations during Cerebral Phaeohyphomycosis.

Authors:  François Barde; Eliane Billaud; Lauriane Goldwirt; Catherine Horodyckid; Vincent Jullien; Fanny Lanternier; Philippe Lesprit; Lucie Limousin; Jérémie F Cohen; Olivier Lortholary
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 2.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

Review 3.  Therapeutic Drug Monitoring of Posaconazole: an Update.

Authors:  Bart G J Dekkers; Martijn Bakker; Kim C M van der Elst; Marieke G G Sturkenboom; Anette Veringa; Lambert F R Span; Jan-Willem C Alffenaar
Journal:  Curr Fungal Infect Rep       Date:  2016-05-07

4.  Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model.

Authors:  Frédéric-Antoine Dauchy; Mélanie Bonhivers; Nicolas Landrein; Denis Dacheux; Pierrette Courtois; Florian Lauruol; Sylvie Daulouède; Philippe Vincendeau; Derrick R Robinson
Journal:  PLoS Negl Trop Dis       Date:  2016-11-17

Review 5.  Pharmacokinetics and Pharmacodynamics of Posaconazole.

Authors:  Lu Chen; Elke H J Krekels; Paul E Verweij; Jochem B Buil; Catherijne A J Knibbe; Roger J M Brüggemann
Journal:  Drugs       Date:  2020-05       Impact factor: 9.546

Review 6.  Clinical Pharmacokinetics of Triazoles in Pediatric Patients.

Authors:  Didi Bury; Wim J E Tissing; Eline W Muilwijk; Tom F W Wolfs; Roger J Brüggemann
Journal:  Clin Pharmacokinet       Date:  2021-05-18       Impact factor: 5.577

Review 7.  Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis.

Authors:  Zorica Jović; Slobodan M Janković; Dejana Ružić Zečević; Dragan Milovanović; Srđan Stefanović; Marko Folić; Jasmina Milovanović; Marina Kostić
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-04       Impact factor: 2.569

8.  Urinary tract aspergillosis in a patient with chronic kidney disease.

Authors:  Linghong Zhou; Huazhen Zhao; Zhongqing Chen; Liping Zhu
Journal:  BMJ Case Rep       Date:  2017-11-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.